MedElevator Войти в исследования
← Поиск публикаций

DOI 10.1038/s41409-025-02787-9

Медицинская библиотека · Bone marrow transplantation · 2025

CAR T-cells in multiple myeloma: the race to the start line.

Bazarbachi Abdul-Hamid, Bhutani Divaya, Hughes Michael Sang, Lentzsch Suzanne, Mapara Markus, Muranski Pawel, Reshef Ran, Wangjam Tamna, Chakraborty Rajshekhar

СтатьяОбзорПеревод пока не подготовлен

Аннотация

The treatment landscape for multiple myeloma is rapidly evolving, driven by T-cell-mediated tumor responses through CAR T-cell therapies and bispecific antibodies. Since KarMMa and CARTITUDE-1 established the activity of idecabtagene vicleucel and ciltacabtagene autoleucel in heavily pretreated disease, efforts have intensified to move them earlier, culminating in KarMMa-3 and CARTITUDE-4, which demonstrated superiority to standard regimens in earlier lines and prompted label expansions. Yet randomized data alone do not capture real-world effectiveness. Emerging cohorts highlight attrition before infusion, product-specific safety signatures with infection-driven non-relapse mortality, and heterogeneous outcomes in high-risk biology such as extramedullary disease, adverse cytogenetics, and early relapse. Access and delivery constraints, including bridging intensity, vein-to-vein intervals, out-of-specification release, and outpatient feasibility, further determine who benefits. This review synthesizes updated randomized and real-world evidence for idecabtagene vicleucel and ciltacabtagene autoleucel, examines challenging populations and emerging toxicities, and delineates operational factors that shape outcomes at scale. We outline where CAR T should displace existing standards, where caution is warranted, and which innovations in targets, constructs, and manufacturing are most likely to advance the start line.

Для цитирования: Bazarbachi Abdul-Hamid, Bhutani Divaya, Hughes Michael Sang, Lentzsch Suzanne, Mapara Markus, Muranski Pawel, Reshef Ran, Wangjam Tamna, Chakraborty Rajshekhar. CAR T-cells in multiple myeloma: the race to the start line.. Bone marrow transplantation. 2025. DOI: 10.1038/s41409-025-02787-9.

Предметные рубрики MeSH

Подготовка и перевод публикации
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…

История · было → стало

Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.

Тип публикации указан по данным источника. Уровень доказательности автоматически не присваивается.